Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.

In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation of progression-free survival and, in some cases, also of overall survival. This led to a substantial increase of advanced disease treatability. In the present review we comprehensively and critically describe the most significant progresses in the therapeutic scenario of MBC according to BC subtype. In particular, we reviewed studies reporting practice-changing data in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive and triple-negative BC, with also a hint to BRCA-related tumors and the emerging HER2-low-positive category.
Competing Interests: Disclosure GG reports personal fees from Eli Lilly and Novartis, outside the submitted work. MVD reports personal fees from Eli Lilly, Exact Sciences, Novartis, Pfizer, Seagen, outside the submitted work. VG reports personal fees from Novartis, Roche, Eli Lilly, MSD, outside the submitted work. The remaining authors declare no competing interests.
(Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)